

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

**(1) CHANGE OF DIRECTORS; AND
(2) CHANGE IN COMPOSITION OF AUDIT COMMITTEE**

The Board announces that, with effect from 5 May 2022:

- (a) Mr. Chengwei Liu has been appointed as a non-executive Director and a member of the Audit Committee; and
- (b) Dr. Yan Wang has resigned as a non-executive Director and a member of the Audit Committee.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND A MEMBER OF THE AUDIT COMMITTEE

The board (the “**Board**”) of directors (“**Directors**”, each a “**Director**”) of Kintor Pharmaceutical Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) hereby announces that Mr. Chengwei Liu (劉澄偉) (“**Mr. Liu**”) has been appointed as a non-executive Director and a member of the audit committee of the Company (the “**Audit Committee**”) with effect from 5 May 2022.

Mr. Liu, aged 52, has been, and is currently the Chairman and President of Suzhou Oriza Holdings Corporation (蘇州元禾控股股份有限公司) since March 2016. From December 1998 to March 2016, Mr. Liu served as a staff member, deputy director, director and deputy executive of Suzhou Industrial Park Administrative Committee (蘇州工業園區管委會). From July 1995 to December 1998, Mr. Liu served as the deputy manager of the delivery department of Suzhou Commodity Exchange (蘇州商品交易所) and a lawyer of Suzhou Future Law Firm (蘇州未來律師事務所). Save for his position as a non-executive Director of the Company, Mr. Liu is currently a director of S.F. HOLDING CO., LTD (a company listed on the Main Board of the Shenzhen Stock Exchange in China) and Zhongji Innolight Co., Ltd. (a company listed on the ChiNext Market of the Shenzhen Stock Exchange in China), respectively.

Mr. Liu holds a master's degree in finance, and is also a senior economist and lawyer.

Mr. Liu has entered into a service contract with the Company for an initial term of three years commencing on 5 May 2022, subject to retirement by rotation and re-election at the general meetings of the Company pursuant to the articles of association of the Company. Such service contract may be terminated by not less than one month's notice in writing served by either party on the other. Pursuant to the service contract, Mr. Liu will not receive any remuneration for his service as a non-executive Director of the Company.

Save as disclosed above, to the best knowledge and belief of the Board and having made all reasonable enquiries, as at the date of this announcement, Mr. Liu (i) has not held any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas during the last three years, (ii) does not have any relationship with any director, senior management or substantial or controlling shareholder of the Company, (iii) does not hold any other positions in the Company or any of its subsidiaries and (iv) does not have, and is not deemed to have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571) of the Law of Hong Kong.

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Mr. Liu as a non-executive Director that need to be brought to the attention of the shareholders of the Company, nor is there any other information that should be disclosed by the Company pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its warm welcome to Mr. Liu to the Board.

RESIGNATION OF NON-EXECUTIVE DIRECTOR AND A MEMBER OF THE AUDIT COMMITTEE

The Board further announces that Dr. Yan Wang (“**Dr. Wang**”) has resigned as a non-executive Director and a member of the Audit Committee with effect from 5 May 2022 due to pursuit of his personal commitments.

Dr. Wang has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board would like to take this opportunity to express its sincere gratitude to Dr. Wang for his valuable contributions to the Company during his tenure of office.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman, Executive Director and CEO

Hong Kong, 5 May 2022

As of the date of this announcement, the executive Directors are Dr. Youzhi Tong and Ms. Yan Lu; the non-executive Directors are Mr. Weipeng Gao, Ms. Geqi Wei and Mr. Chengwei Liu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*